Potential role of macrophage migration inhibitory factor in adult-onset Still's disease.
Becker
H
H
Gaubitz
M
M
Domschke
W
W
Willeke
P
P
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D000068800:Etanercept; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D019746:Intramolecular Oxidoreductases / Q000097:blood* / Q000502:physiology*; D008263:Macrophage Migration-Inhibitory Factors / Q000097:blood* / Q000502:physiology*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012720:Severity of Illness Index; D016706:Still's Disease, Adult-Onset / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D008263:Macrophage Migration-Inhibitory Factors; D018124:Receptors, Tumor Necrosis Factor; D002097:C-Reactive Protein; D005293:Ferritins; D019746:Intramolecular Oxidoreductases; C515598:MIF protein, human; D000068800:Etanercept; D011241:Prednisone; D008727:Methotrexate